scispace - formally typeset
Open AccessJournal ArticleDOI

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

TLDR
Authors/Task Force Members (François Macha, Colin Baigentb,∗∗,2, Alberico L. Catapanoc), ESC Committee for Practice Guidelines (CPG) (Stephan Windeckeraa), ESC National Cardiac Societies (Djamaleddine Nibouchean, Parounak H. Patelcl)
About
This article is published in Atherosclerosis.The article was published on 2019-09-02 and is currently open access. It has received 2972 citations till now. The article focuses on the topics: Lipid modification & Very low-density lipoprotein.

read more

Citations
More filters

Standards of Medical Care in Diabetes

TL;DR: These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to evaluate the quality of care.
Journal ArticleDOI

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Frank L.J. Visseren, +105 more
Journal Article

Effects of the amount and intensity of exercise on plasma lipoproteins: Editor's comments

TL;DR: The highest amount of weekly exercise, with minimal weight change, had widespread beneficial effects on the lipoprotein profile, seen most clearly with the high amount of high-intensity exercise.
Journal ArticleDOI

Atorvastatin in Patients With Type 2 Diabetes Mellitus Undergoing Hemodialysis

TL;DR: Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.
References
More filters
Journal ArticleDOI

Fluvastatin and perioperative events in patients undergoing vascular surgery.

TL;DR: In patients undergoing vascular surgery, perioperative fluvastatin therapy was associated with an improvement in postoperative cardiac outcome and Fluvastatin Therapy was not associated with a significant increase in the rate of adverse events.
Journal ArticleDOI

Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial

TL;DR: Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects, and in stable patients, intensive statin Therapy provides long-term reduction inclinical events when compared with standard therapy.
Journal ArticleDOI

Animal models of atherosclerosis.

TL;DR: The development of a model in which intra-plaque microvessels, haemorrhages, spontaneous atherosclerotic plaque ruptures, myocardial infarction and sudden death occur consistently is developed, which can be used as a validated model in pre-clinical studies to evaluate novel plaque-stabilizing drugs.
Journal ArticleDOI

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

TL;DR: Antisense inhibition of Apolipoprotein C-III in preclinical models and in a phase I clinical trial with healthy subjects produced potent, selective reductions in plasma apoC-III and triglyceride, 2 known risk factors for cardiovascular disease.
Related Papers (5)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

François Mach, +120 more